AR128285A1 - Formulaciones farmacéuticas y métodos para el tratamiento de trastornos metabólicos y hepáticos - Google Patents

Formulaciones farmacéuticas y métodos para el tratamiento de trastornos metabólicos y hepáticos

Info

Publication number
AR128285A1
AR128285A1 ARP230100109A ARP230100109A AR128285A1 AR 128285 A1 AR128285 A1 AR 128285A1 AR P230100109 A ARP230100109 A AR P230100109A AR P230100109 A ARP230100109 A AR P230100109A AR 128285 A1 AR128285 A1 AR 128285A1
Authority
AR
Argentina
Prior art keywords
alkyl
haloc1
alkoxy
group
membered heteroaryl
Prior art date
Application number
ARP230100109A
Other languages
English (en)
Spanish (es)
Inventor
Brian Lian
Geoffrey E Barker
Maureen Barnes
Kader Yagiz
Original Assignee
Viking Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viking Therapeutics Inc filed Critical Viking Therapeutics Inc
Publication of AR128285A1 publication Critical patent/AR128285A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ARP230100109A 2022-01-18 2023-01-18 Formulaciones farmacéuticas y métodos para el tratamiento de trastornos metabólicos y hepáticos AR128285A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263300538P 2022-01-18 2022-01-18

Publications (1)

Publication Number Publication Date
AR128285A1 true AR128285A1 (es) 2024-04-10

Family

ID=87348890

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100109A AR128285A1 (es) 2022-01-18 2023-01-18 Formulaciones farmacéuticas y métodos para el tratamiento de trastornos metabólicos y hepáticos

Country Status (11)

Country Link
US (1) US20250171499A1 (cg-RX-API-DMAC10.html)
EP (1) EP4466022A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025502383A (cg-RX-API-DMAC10.html)
KR (1) KR20240136386A (cg-RX-API-DMAC10.html)
CN (1) CN118946368A (cg-RX-API-DMAC10.html)
AR (1) AR128285A1 (cg-RX-API-DMAC10.html)
AU (1) AU2023208627A1 (cg-RX-API-DMAC10.html)
CA (1) CA3248728A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024008795A (cg-RX-API-DMAC10.html)
TW (1) TW202339789A (cg-RX-API-DMAC10.html)
WO (1) WO2023141044A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2025209422A1 (en) * 2024-04-01 2025-10-09 Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. Incretin analogs as glp-1, gip and glucagon receptor triple agonists and uses thereof
WO2026092580A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases
WO2026092581A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata
WO2026092583A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101243648B1 (ko) * 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
KR20250044806A (ko) * 2018-07-23 2025-04-01 일라이 릴리 앤드 캄파니 요법을 위한 gip/glp1 공효능제 사용 방법
KR20240118914A (ko) * 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
JP2025523981A (ja) * 2022-07-20 2025-07-25 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための医薬製剤及び方法

Also Published As

Publication number Publication date
AU2023208627A1 (en) 2024-08-01
EP4466022A4 (en) 2025-12-10
WO2023141044A1 (en) 2023-07-27
MX2024008795A (es) 2024-09-04
EP4466022A1 (en) 2024-11-27
US20250171499A1 (en) 2025-05-29
CA3248728A1 (en) 2023-07-27
KR20240136386A (ko) 2024-09-13
JP2025502383A (ja) 2025-01-24
CN118946368A (zh) 2024-11-12
TW202339789A (zh) 2023-10-16

Similar Documents

Publication Publication Date Title
AR119731A1 (es) Inhibidores del inflamasoma nlrp3
PY2240956A (es) Nuevos Compuestos bicíclicos y sus usos
AR088919A2 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y uso
AR108906A1 (es) Heterociclos de biarilmetilo
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR113299A1 (es) Compuestos de isoindolina
AR127404A1 (es) Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
JP2013541566A (ja) カルバゾール及びカルボリンの誘導体ならびにその調製及び治療法上の応用
AR123757A1 (es) Inhibidores de las cinasas raf
AR104555A1 (es) SULFONAS TRICÍCLICAS COMO MODULARES DE RORg
PE20220704A1 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos
PE20201280A1 (es) Amidas de imidazopiridina sustituidas y su uso
AR117206A1 (es) Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer
CO2024013669A2 (es) Derivados de quinolina como moduladores del receptor x2 de la proteína g relacionados con mas y productos relacionados
AR118729A1 (es) Inhibidor selectivo de la jak1 quinasa
AR130709A1 (es) Compuesto de ciclopentano
AR015751A1 (es) Compuestos ligandos azabiciclicos de receptores 5ht1, compuestos para uso en la manufactura de un medicamento para modular la neurotransmisionserotonergica, composiciones farmaceuticas, procedimientos de tratamiento y compuestos utiles para la preparacion de dichos ligandos
AR125312A1 (es) Derivados heterocíclicos, composiciones farmacéuticas y su uso en el tratamiento o la mejora del cáncer
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
PY2167570A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
AR016416A1 (es) Fenil-alquil-imidazoles, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de un medicamento
AR120169A1 (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4
AR131812A1 (es) Compuestos y composiciones para la degradación selectiva de proteínas diseñadas
AR070949A1 (es) Compuestos derivados de sulfamato de uso medico, medicamentos y composiciones farmaceuticas que los comprenden, procedimientos para preparar estos compuestos y su uso
AR088003A1 (es) Derivados de metansulfonamida sustituidos con amina como ligandos del receptor de vanilloide